Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113931 · ClinicalTrials.gov registry record · Phase 3
Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 495
- Enrollment target
NCT01113931 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 495 participants.
The verdict
NCT01113931, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 495 participants
- Enrollment target
Study Summary
Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days, for the treatment of uncomplicated urogenital Chlamydia trachomatis infection. Primary efficacy endpoint is microbiological cure at Day 28. Safety assessments are adverse events, changes in vital signs and laboratory test results.
Interventions
- DRUG Doxycyline Hyclate tablet
- DRUG Vibramycin (doxycyline hyclate) capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113931
The ClinicalTrials.gov registry entry for NCT01113931 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxycyline Hyclate tablet is the first listed.
NCT01113931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01113931 about?
NCT01113931 is a clinical study titled "Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin". Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days, for the treatment of uncomplicated urogenital Chlamydia trachomatis infection. Primary efficacy endpoint is micro...
What is the current status of trial NCT01113931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 495 participants. The study started on 2010-04. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01113931?
The interventions under investigation include: Doxycyline Hyclate tablet (DRUG), Vibramycin (doxycyline hyclate) capsule (DRUG).
Who is sponsoring clinical trial NCT01113931?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.